← Back to Search

Neuromodulation

Transcranial Magnetic Stimulation for Depression

Phase 1

Waitlist Available

Research Sponsored by Sunnybrook Health Sciences Centre

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Receiving a neuromodulation (rTMS) treatment for depression at the HCN

Age 18-80, inclusive

Must not have

History of seizure disorder

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 2 years

Awards & highlights

No Placebo-Only Group

Summary

This trial aims to see how a treatment called repetitive transcranial magnetic stimulation (rTMS) affects brain function in people with depression. Depression can disrupt the brain's network that controls thinking, emotions

Who is the study for?

This clinical trial is for individuals experiencing depression. Participants will undergo a non-invasive treatment called repetitive transcranial magnetic stimulation (rTMS). The study requires participants to have their brain activity monitored using a quick and easy EEG technology.

What is being tested?

The trial is testing the impact of rTMS on brain function in people with depression. Researchers are using a new, faster method of EEG to track changes in brain activity related to cognitive, emotional, and behavioral regulation during and after treatment.

What are the potential side effects?

rTMS is generally well-tolerated but can sometimes cause discomfort at the stimulation site, headache, lightheadedness, or tingling. It's rare but seizures could occur. Side effects from qEEG are minimal since it's non-invasive.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am currently undergoing rTMS treatment for depression.

Select...

I am between 18 and 80 years old.

Select...

I have been diagnosed with depression according to DSM 5.0.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

I have a history of seizures.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 2 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~2 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Change in Depression Score on the Montgomery-Asberg Depression Rating Scale (MADRS)

Secondary study objectives

Changes in functional connectivity

Relapse rates measured on the Montgomery-Asberg Depression Rating Scale

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups

Active Control

Group I: Cluster Maintenance TMSActive Control1 Intervention

Participants will receive a cluster of treatments consisting of 5 treatments over two consecutive week days (either 2 treatments on day 1 followed by 3 treatments day 2 or vice-versa, based on scheduling)

Group II: Gradual Tapering TMSActive Control1 Intervention

Participants will receive a once daily treatment protocol delivered once weekly for 1 month, and gradually tapering the frequency of treatment to 1 treatment every 2 weeks for 2 months

0 / 4Eligibility criteria met